Pharmacologic inhibition of driver mutations in AML (FLT3-ITD) or CML (BCR-ABL) also restored SIRT7 levels in cell lines and patient samples. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.